Back
Speaker illustration

Doctor Roopinder Sandhu

University of Calgary, Calgary (Canada)

Member of:

European Society of Cardiology

Presentations

Cost-effectiveness of apixaban vs aspirin for the reduction of thrombo-embolism in high-risk patients with device-detected atrial fibrillation: insights from the ARTESiA trial

Event: ESC Congress 2025

Topic: Health Economics

Session: Public health and health economics

Access
Like
Thumbnail

The current and future total health care costs of atrial fibrillation

Event: ESC Congress 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Prognosis and outcome in patients with atrial fibrillation

Access
Like
Thumbnail

A polygenic risk score predicts atrial fibrillation in patients with coronary artery disease without severe systolic dysfunction.

Event: ESC Congress 2023

Topic: Epidemiology, Prognosis, Outcome

Session: Risks and screening for atrial fibrillation

Access
Like
Thumbnail

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources